Personalis Part II: Per-Test Economics, Volume Scenarios, and a Risk-Adjusted Price Target

Since We're Here, We Might As Well

Follow-up to the original Personalis BOTN. For the first post, please refer to the link here. Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

Two updates worth front-loading before the unit economics work.

First, the immunotherapy coverage decision arrived on May 12, 2026, considerably earlier than BTIG’s mid-2026 window and against a guidance baseline that explicitly excluded it. MolDX expanded coverage of NeXT Personal to include immunotherapy monitoring across late-stage solid tumors, supported by the Vall d’Hebron published evidence. The stock spiked roughly 19% on the news, which both validates the coverage ladder framework and meaningfully de-risks one of the three named catalysts from the original post. Two more (CRC and bladder) remain outstanding, but the most contested one is now live.

Second, the November 2025 MolDX rate update gave us hard numbers to anchor the per-test economics. The initial Dx Breast MRD Recurrence Monitoring Test (the tissue-plus-baseline-plasma test, ordered once per cancer diagnosis) reimburses at $4,266. The Single Plasma Test (the recurring surveillance assay, ordered up to four times a year for up to six years) reimburses at $1,164. Those are the two prices that drive everything that follows.

The original post established why the technology and the coverage ladder matter but what it didn’t do is build a defensible model of what each test earns, how volume scales, where gross margin lands as the mix shifts, and what the resulting valuation range looks like under explicit assumptions. So that’s what this piece does.